Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galunisertib plus nivolumab in advanced refractory solid tumors, non-small cell lung cancer, and hepatocellular carcinoma
2015-002093-20Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of galunisertib and nivolumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose of Galunisertib in Combination with Nivolumab. Started Oct 2016; status: completed.
02
Drugs
galunisertibnivolumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2015-002093-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002093-20.